Abstract 165P
Background
Lenvatinib is a new first-line molecular target drug for hepatocellular carcinoma (HCC) that is available worldwide. We evaluated the efficacy and safety of lenvatinib for unresectable HCC.
Methods
This study population included thirty-seven patients that we could follow from 42 patients who received lenvatinib between April 2018 and May 2019 in our hospital. We evaluated the lenvatinib treatment profile, the clinical response (according to mRECIST), adverse events (according to CTCAE v.4.0), progression free survival (PFS), overall survival (OS), conversion therapy and the tumor response after progressive disease (PD) and serious adverse events (sAEs).
Results
The study population included 34 male patients (91.9%). Eleven patients were positive for HBV, 14 were positive for HCV, 6 had a history of alcohol intake. The Child Pugh scores (CPS) were as follows: 5 (n = 27), 6 (n = 7), 7(n = 3). Fifteen patients had BCLC stage B and 22 had C. The reasons for lenvatinib included TACE failure/refractoriness (35.3%), vascular invasion (32%), extrahepatic spread: (27.0%), PD after other molecular target therapies (16.2%) . The initial dose was 12 mg (90%) in patients with a body weight of > 60 kg, 8 mg (68.8%) in patients with a body weight of < 60 kg; in these two groups, 50.0% and 66.6% of patients received a half-dose reduction after one month. The tumor responses were classified as follows: objective response rate (ORR), 35.1%; disease control rate (DCR), 70.3%; PFS, 7.3 months (95% CI 4.9-11.2); OS, the median OS was not reached. There was no significant differences in the CPS between before and after therapy (p = 0.68). The rates of AEs (any grade/grade ≥3) were as follows: hypertension (37.8/0%), protein urea (29.7/13.5%), hypothyroidism (16.2/0%), fatigue (8.1/2.7%), hand-foot skin reaction (5.4/0%), hepatic encephalopathy (8.1%), respectively. The ORR and DCR of the grade ≥3 and grade <2 groups did not differ to a statistically significant extent. In the grade ≥3 group, 4 patients obtained a clinical benefit, however could not receive chemotherapies because of a poor performance status (≥3).
Conclusions
Lenvatinib is good therapeutic drug for advanced HCC, however it is very important to pay attention to sAEs in patients who show a clinical benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract